Novo Nordisk , the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil ...

Danish drugmaker Novo Nordisk is looking at an early launch of its blockbuster weight-loss drug Wegovy in India to better ...

Danish pharmaceutical company Novo Nordisk is set to launch its anti-diabetes and weight-loss drug Wegovy in India, aiming to ...

Last week, the Centers for Medicare & Medicaid Services said it will not go ahead with a plan from the Biden administration ...

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire ...

AbbVie’s Skyrizi and Rinvoq were practically unshakeable atop the monthly TV drug ad spending rankings, ultimately leading ...

Danish pharmaceutical company Novo Nordisk plans to introduce its weight-loss drug Wegovy in India earlier than planned to ...

STORY: Weight-loss drug Wegovy has driven Novo Holdings to fresh highs.The company said Wednesday (April 2) it nearly doubled ...

Novo Nordisk is preparing to launch its blockbuster obesity drug Wegovy (injectable semaglutide) in India later this year, the company told Business Today, setting the stage for a high-stakes battle ...

Novo Nordisk (NVO), the company behind Ozempic and Wegovy, announced that it will invest 6.4 billion reais (about $1.09 ...

Novo Nordisk will invest $1.09 billion in Brazil to enhance production of injectable drugs for obesity and diabetes. This ...